In the last fiscal year, Press On donated more than $78,000 to Dr. Donald Durden’s research of PL-3 Kinase Inhibitor and Targeted Therapies for neuroblastoma. Click Here to read a report from Dr. Durden outlining his progress.
Press on also directed $10,000 to Memorial Sloan Kettering Cancer Center (MSKCC) to support a team of dedicated neuroblastoma
researchers who are investigating exciting treatment options that they believe could help save more children with neuroblastoma. MSKCC is working on several pioneering treatments including a humanized version of the 3F8 antibody, a mouse-based 3F8 antibody that attaches to neuroblastoma cells and kills them. The antibody, developed by MSKCC’s Dr. Cheung, also trains a child’s immune system to attack and kill neuroblastoma. Since first used in 1987, 3F8 treatment has greatly improved survival without lasting side effects. The mouse-based antibody’s primary drawback is that it can be rejected by the child’s own immune system. MSKCC is researching chimeric and humanized v ersions of 3F8 to alleviate this issue and make it more effective for a greater number of patients. MSKCC is also workng on several other promising treatments for neuroblastoma, including different antibodies and a vaccine.
